Roche has announced that its new weight loss drugs will be part of a broader strategy to address obesity. CEO Thomas Schinecker highlighted promising early trial results for two of the company’s weight loss drug candidates, emphasizing their “best in disease potential.” These drugs, part of the class known as GLP-1/GIPs which mimic natural hormones to regulate insulin, aim to set Roche apart in the competitive obesity medication market dominated by Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound.
In addition to these weight loss treatments, Roche is developing medications like GYM329, which targets muscle loss—a common side effect of weight loss. Schinecker believes this comprehensive approach can counteract the “yo-yo effect” often seen with dieting and enhance the overall efficacy of obesity treatments.
Although entering the market later than rivals, Roche’s recent trials show promise. Their experimental pill CT-996 resulted in a 6.1% weight loss over four weeks in obese patients without Type 2 diabetes. Furthermore, the CT-388 drug showed an 18.8% weight loss over 24 weeks in earlier trials. Both drugs were part of Roche’s acquisition of U.S. biotech firm Carmot Therapeutics.
Schinecker affirmed the company’s commitment to expanding in this market, which analysts project could reach a value of $200 billion by 2030. He noted that addressing cardiovascular diseases and obesity constitutes a major unmet medical need, emphasizing that Roche remains open to strategic acquisitions.
These comments follow Roche’s report of strong sales growth for the first half of the year, prompting an upward revision of its annual outlook. Analysts from Citi highlighted upcoming trial data in September as a focal point for investors. Key findings will be presented at the European Association for the Study of Diabetes event in Madrid and at Roche’s annual pharma day in London.
Original Story https://www.cnbc.com/2024/07/25/roche-wegovy-obesity-rival-to-be-part-of-a-suite-of-weight-loss-drugs.html
Category :
Tags:
